insights_auto
为什么 LGND 上涨了 3.09%?
深入探索chevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
US$311.13
arrow_upward
+3.09%(+9.32) 1 天
US$311.13
0.00% (0.00)
bedtime盘后交易
休市： 10月12日, GMT-4 16:00:02 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 LGND 生成关键数据洞见…
开盘价
US$302.50
最高价
US$311.86
最低价
US$300.00
市值
62.03亿
平均成交量
24.66万
成交量
17.32万
市盈率
33.09
52 周最高价
US$326.63
52 周最低价
US$175.89
每股收益
US$9.40
Beta 版
1.06
流通股数
1993.60万
员工人数
47
开盘价
US$302.50
最高价
US$311.86
最低价
US$300.00
市值
62.03亿
平均成交量
24.66万
成交量
17.32万
市盈率
33.09
52 周最高价
US$326.63
52 周最低价
US$175.89
每股收益
US$9.40
Beta 版
1.06
流通股数
1993.60万
员工人数
47
新闻报道
来自网络来源和新闻合作伙伴
Investing.com
·
1天前
Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock
Investing.com Nigeria
·
1天前
Form 4 Ligand Pharmaceuticals Incorporated For: 11 October By Investing.com
资料
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc简介